Table 1.

Patient characteristics

Patients, n	100
Age, median (range)	72 (46–82)
Initial tumor stage, n (%)
pT2a	1 (1%)
pT2c	20 (20%)
pT3a	25 (25%)
pT3b	51 (51%)
pT4	3 (3%)
Initial nodal stage, n (%)
pN0	54 (54%)
pN1	42 (42%)
pNx/cN0	2 (2%)
Unknown	2 (2%)
Positive surgical margins, n (%)	52 (52%)
ISUP score, n (%)
1	2 (2%)
2	12 (12%)
3	25 (25%)
4	18 (18%)
5	43 (43%)
PSA at RP (ng/ml), median (range)	13.9 (0.05–427)
Postoperative PSA (ng/ml), median (range)	0.6 (0.0–40.1)
Patients with bcP/bcR, n (%)	76 (76%)/24 (24%)
Time between RP and bcR (month), median (range)	22.5 (2–148)
PSA at PSMA-PET/CT (ng/ml), median (range)	1.4 (0.1–40.1)
PSA at PSMA-PET/CT in patients with bcP (ng/ml), median (range)	1.7 (0.1–40.1)
PSA at PSMA-PET/CT in patients with bcR (ng/ml), median (range)	0.6 (0.3–5.1)
Number of lymph node metastases on PSMA-PET/CT, n (%)
1	35 (35%)
2	23 (23%)
≥ 3	42 (42%)
Patients with local recurrence on PSMA-PET/CT, n (%)	29 (29%)

Abbreviations: bcP biochemical persistence; bcR biochemical recurrence; ISUP International Society of Urological Pathology; n number; PSA prostate-specific antigen; RP radical prostatectomy